For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 0 | 0 | - | 602 |
| Research and development | 5,011 | -430 | 10,837 | 6,554 |
| General and administrative | 3,218 | 3,122 | 3,655 | 3,456 |
| Total operating expenses | 8,229 | 2,692 | 14,492 | 10,010 |
| Loss from operations | -8,229 | -2,692 | -14,492 | -9,408 |
| Interest income and other expense, net | - | - | - | 808 |
| Interest expense | 19 | 29 | 36 | 71 |
| Interest and other income, net | 36 | 654 | 487 | - |
| Net loss and comprehensive loss | -8,212 | -2,067 | -14,041 | -8,671 |
| Comprehensive income (loss), net of tax, attributable to parent | - | - | - | -8,671 |
| Net loss per share, basic | -14.58 | -3.5 | -0.32 | -0.21 |
| Net loss per share, diluted | -14.58 | -3.5 | -0.32 | -0.21 |
| Weighted average number of shares outstanding, basic, total | 563,066 | 591,137 | 43,944,946 | 41,302,599 |
| Weighted average number of shares outstanding, diluted, total | 563,066 | 591,137 | 43,944,946 | 41,302,599 |
SPRUCE BIOSCIENCES, INC. (SPRB)
SPRUCE BIOSCIENCES, INC. (SPRB)